

## Special Issue

# Advanced Research in Thyroid and Parathyroid Diseases

### Message from the Guest Editor

Thyroid and parathyroid diseases encompass a wide spectrum of conditions, ranging from benign disorders to aggressive malignancies. Thyroid cancer remains one of the most prevalent endocrine malignancies, with its incidence continuing to rise globally.

This Special Issue aims to highlight innovative developments in the diagnosis and treatment of thyroid and parathyroid diseases. We welcome contributions that explore innovative therapeutic strategies, precision medicine applications, and the role of tumor microenvironment modulation in disease progression. The scope of this Special Issue includes emerging biomarkers for prognosis and treatment selection, the mechanisms of treatment resistance, advances in systemic therapies, and novel surgical and radiotherapeutic techniques. We particularly welcome the submission of studies that connect laboratory discoveries with clinical applications, offering new perspectives regarding the evolving landscape of thyroid and parathyroid disease management. Through this collection, we seek to provide a comprehensive and up-to-date resource that informs future research and clinical practice.

---

### Guest Editor

Dr. Anping Su

Division of Thyroid & Parathyroid Surgery, Department of General Surgery, West China Hospital Sichuan University, Chengdu, China

---

### Deadline for manuscript submissions

30 September 2025



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/235063](https://mdpi.com/si/235063)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).